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Abstract
Numerous individual studies evaluating the relationship between CD44V6 over-expression and prognostic impact in
patients with osteosarcoma (OS) have yielded in conclusive results. This meta-analysis aimed to determine the value
of cell adhesion molecule CD44V6 in prognosis of OS by conducting a systematic review and meta-analysis. A
comprehensive search was conducted using PubMed (medline), Embase, ISI Web of Knowledge, Springer, the
Cochrane Library, Scopus, BioMed Central, ScienceDirect, Wanfang, Weipu, and China National Knowledge Internet
(CNKI) databases from inception through May 26, 2015. All available articles written in English or Chinese that
investigated the expression of CD44V6 and the prognosis of OS were included. The quantity of the studies was
evaluated according to the critical review checklist of the Dutch Cochrane Centre proposed by MOOSE. Finally, a
total of eight studies with 486 OS patients were involved and the results indicated that the positive expression of
CD44V6 predicts neoplasm metastasis (RR = 1.76, 95 % CI 1.38–2.25, p < 0.00001), and poor survival in OS with the
pooled HR of 1.53 (95 % CI 1.25–1.88, p < 0.0001). No significant heterogeneity was observed among all studies. In
conclusion, the present meta-analysis and systematic review strongly suggest that CD44V6 over-expression is
associated with overall survival rate and metastasis in OS, and may be used as a prognostic biomarker to guide the
clinical therapy for OS.
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Introduction
Osteosarcoma (OS) is the most common malignancy
originating from the bone that mainly afflicts the
pediatric age group and young adults [1, 2]. It is the sec-
ond leading cause of cancer-related death in adolescents
due to the fact that most of the patients involve in fatal
metastasis. It is approximately 20–25 % of newly diag-
nosed patients have detectable lung-related metastasis
[3, 4]. Despite recent improvement in surgical, radiother-
apy and neoadjuvant chemotherapy, the long-term sur-
vival of patients with OS is still less than 50 % [5]. At
present, the ability to predict the prognosis and metastasis
of OS is limited because the mechanism of oncogenetic is
still not fully elucidated. So far, the clinical prognostic
factors were still demographics (age and sex), site, stage,
tumor size, and the response to chemotherapy. Therefore,
identifying prognostic markers in OS could be informative
for selecting proper management. In recent years, the ex-
pression of CD44 variant isoform V6 (CD44V6) has been
identified as one of the potential prognostic and meta-
static biomarkers for OS.
Biomarkers are used as tools in cancer prognosis and
metastasis [6]. CD44 is a kind of trans-membrane glyco-
protein and the structure contains seven extracellular
domains, a trans-membrane domain, and a cytoplasmic
domain [7]. Due to the alternative splicing of CD44, at
least 10 variants are generated during transcription [8].
CD44V6 is one of the variant isoforms (CD44V), which
has been reported to regulate the extracellular matrix, pro-
mote cell motility, and suppress tumor apoptosis [9–12].
In fact, CD44V6 has been implicated in promoting tumor
progression [13]. There are increased levels of CD44V6,
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which could serve as a prognostic marker in various solid
tumors, including myxofibrosarcoma [14], gastric cancer
[15], colorectal cancer [16], non-small-cell lung cancer
[17], esophageal squamous cell carcinoma, [18] and hepa-
tocellular carcinoma [19].
Many published data suggested that over-expression
of CD44V6 was associated with high risk of tumor me-
tastasis and worse survival in patients with OS. How-
ever, some other studies showed controversial results
and no consensus had been reached. To investigate the
relationship between the potential biomarker and the
clinical outcome, we conducted a meta-analysis of all
available studies relating CD44V6 expression with pa-
tients in OS.
Methods
Search strategy and selection criteria
The PubMed (medline), Embase, ISI Web of Knowledge,
Springer, the Cochrane Library, Scopus, BioMed Central,
ScienceDirect, Wanfang, Weipu, and China National
Knowledge Internet (CNKI) databases were used to con-
duct a comprehensive search for studies that evaluated
the accuracy of CD44V6 for the metastasis and progno-
sis of OS. In addition to the electronic databases which
published between inception and May 26, 2015, we also
searched the reference list of each primary study and
of previous systematic reviews. The search strategy
included the following keywords variably combined
by “CD44V6”, “CD44 variation 6” “osteosarcoma”, and
“bone tumor”.
The present meta-analysis was conducted totally fol-
lowing the guidelines of preferred reporting items for
meta-analysis of observational studies in epidemiology
group (MOOSE) and MOOSE checklist for our study is
shown in Additional file 1: Table S1.
Inclusion and exclusion criteria
Inclusion criteria: (1) measurement of CD44V6 in OS
using commercial reagents; (2) pathological diagnosis (gold
standard) confirmed for newly diagnosed patients with OS;
(3) the studies had to provide sufficient information to
construct the 2 × 2 contingency table; and (4) publications
written in English or Chinese.
Exclusion criteria: (1) OS diagnosed without a biopsy
and there was no clear cut-off value in the literature;
(2) similar studies from the same author as well as
multiple duplicate data in the different works, exclud-
ing earlier and smaller sample data; (3) animal experi-
ments, reviews, correspondences, case reports, talks,
letters, expert opinions, and editorials without original
data; and (4) studies of non dichotomous CD44V6 ex-
pression levels and absence of survival outcome were
excluded.
Quality assessment
The included studies were evaluated according to the
critical review checklist of the Dutch Cochrane Centre
proposed by MOOSE [20]. The key points were as fol-
lowing: (I) enough information of the carcinoma, (II)
clear description of outcome assessment, (III) clear de-
scription of study design, (IV) clear description of
CD44V6 measurement, (V) clear description of cut-off
of CD44V6, and (VI) sufficient period of follow-up. The
studies without mentioning all these points were
excluded.
Data extraction
Two investigators (YYZ and XC) evaluated the eligibility
of all retrieved studies and extracted the relevant data
independently. Extracted databases were then cross-
checked between the two authors to rule out any dis-
crepancy. Data regarding the following for each included
studies were extracted independently: first authors’ sur-
name, publication year, CD44V6 assessment methods,
and the cut-off definition. Corresponding authors were
contacted if further information was needed. The study
was excluded if no response was received after sending a
reminder.
Statistical analysis
The statistical analysis was carried out using the Review
Manager (RevMan) software version 5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration,
Copenhagen, Denmark) and STATA 12. All these hazard
ratios and 95 % confidence interval (CI) were calculated.
Pooled HR was calculated using a fixed-effects model or
random-effects model to evaluate the relationship be-
tween CD44V6 expression and metastasis or overall sur-
vival. I2 statistics were used to evaluate the between-study
heterogeneity analysis in this study. The fixed-effects
model was used when there was no significant heterogen-
eity between the included studies (I2 < 30 %). Sensitivity
analysis was used to shows influence by any individual
study. Publication bias was estimated using a funnel plot
with a Begg’s linear aggression test; funnel plot asymmetry




The initial search retrieved a total of 764 references that
related to the metastasis or prognosis of CD44V6 in OS.
After duplicated data removed, 648 articles were left.
After screening titles and abstracts of identified articles,
626 articles were excluded because they were not related
to the current study according to the exclusion criteria.
Upon a further full text review, we excluded another 14,
and 8 studies were included in our study [21–28] (Fig. 1).
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Fig. 1 Schematic representation of the study selection
Table 1 Characteristics of studies included in the metastasis meta-analysis
Study Year Age
(median)




CD44V6 positive CD44V6 negative
Metastasis Total Metastasis Total
Deng et al. 2013 18.3 ZSGB-BIO 90 IHC >6 score 38 59 12 31
Guo et al. 2007 18.6 ZSGB-BIO 49 IHC >5 % 16 27 5 22
Hu et al. 2009 19 Santa Cruz 87 IHC >3 score 25 45 12 42
Kim et al. 2002 17 Zymed 50 IHC >50 % 4 26 6 24
Kuryu et al. 1999 19 R&D 39 IHC >10 % 13 18 10 21
Li et al. 2008 23.3 Maixin 35 IHC >0 % 14 19 3 16
Zhu et al. 2014 25 ZSGB-BIO 66 IHC >1 score 39 56 5 10
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The main characteristics of the included studies were
summarized in Tables 1 and 2. In summary, immunohis-
tochemistry (IHC) was used for all studies to determine
the expression of CD44V6. The results were judged by
cut-off in two ways: percentage of positivity and immuno-
reactivity (intensity) score (IRS).
Meta-analysis
The intensity of relationship between the expression
levels of CD44V6 and overall survival or metastasis were
described as hazard ratios (HRs). For studies evaluating
the overall survival and metastasis, STATA 12 and Rev-
Man 5.3 showed there was no significant between-study
heterogeneity among those studies for the overall sur-
vival of CD44V6 (I2 < 30 %), so the fixed-effect model
was used to determine the pooled HR with correspond-
ing 95 % CI. As shown in Figs. 2 and 3, the combined
HR for all eligible studies evaluating CD44V6 over-
expression on overall 5-years disease-free survival and
metastasis was 1.53 (95 % CI 1.25–1.88, p < 0.0001, I2 =
0 %) and 1.76 (95 % CI 1.38–2.25, p < 0.00001, I2 =
18 %), respectively. Sensitivity analysis was used to
evaluate the stability of results. No matter which study
removed, the heterogeneity does not change signifi-
cantly, suggesting that the results of our analysis do not
overly rely on one study and the conclusions are stable.
These results suggest that CD44V6 over-expression was
an indicator of poor prognosis and metastasis for OS
patients.
Publication bias
Funnel plot with Revman was used to evaluate the publi-
cation bias of the literatures. The shape of the funnel
plot did not reveal any evidence of obvious asymmetry
(Figures not shown).
To validate the result, we also performed a Begg’s
funnel plot with STATA, and no publication bias was
found of both metastasis and prognosis in OS (z = 0.00;
p > 0.05).
Discussion
OS is a life threatening primary bone neoplasm that
often occurs in teenagers. Disease free survival escalated
from <20 % prior to the introduction of effective chemo-
therapy to around 60 % and overall survival to 60–70 %
[29]. With 20–25 % having detectable metastases at
diagnosis, OS is characterized by a high propensity for
metastasis, mostly to the lungs. The overall survival rate
decreases to 30 % when metastasis is detected at the
time of diagnosis. Despite early detection screening pro-
tocols, improved surgical techniques, advanced radio,
and chemotherapeutic regimens, limited improvements
to predict the prognosis of OS patients have been
achieved over the past 20 years. Therefore, the update of
early prognostic biomarkers is urgently needed to adapt
the proper therapy to the malignancy. Many researchers
have reported that high expression of certain cell surface
markers indicates bad clinical features and poor progno-
sis, and CD44V6 is one of the potential prognostic
markers for OS.
Table 2 Characteristics of studies included in the 5-year survival meta-analysis
Study Year Age
(median)




CD44V6 positive CD44V6 negative
Metastasis Total Metastasis Total
Deng et al. 2013 18.3 ZSGB-BIO 90 IHC >6 score 56 59 20 31
Kuryu et al. 1999 19 R&D 39 IHC >10 % 14 18 9 21
Lin et al. 2002 22 Maixin 70 IHC >2 score 58 64 4 6
Zhu et al. 2014 25 ZSGB-BIO 66 IHC >1 score 53 56 6 10
Fig. 2 CD44V6 expression and metastasis of osteosarcoma patients
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CD44 is a trans-membrane glycoprotein, and some
variant isoforms of CD44 are reportedly associated with
increased invasion, metastasis, and poor prognosis [30],
particularly the CD44V6 [13]. CD44V6 promoting the
metastasis of cancer has been documented and the
mechanism may be attributed to its interactions with
various components of the extracellular matrix. Several
published data have suggested that CD44V6 expression
is related to metastatic potential, prognosis, and the bio-
logic properties of human malignancies. CD44V6 was
found in 69 % of prostate cancer cases [31], 26 % of
non-Hodgkin’s lymphomas cases [32], 13 % of ovarian
cancer cases [33], 55 % of cervical cancer [34], and 46 %
of OS [35]. There are also studies showing that the pres-
ence of CD44V6 participated in the MAPK and the
PI3K/Akt signaling pathways [36, 37]. Nakajima et al.
suggested that CD44V6 could be an onco-protein in the
bone tissue, which could be expressed in the metasta-
sized OS [38]. The prognostic value of CD44V6 for pa-
tients with cancer has also been studied in various solid
tumors. To our knowledge, no systematic meta-analysis
in evaluating the prognostic values of CD44V6 and OS
has been published.
Eight publications including 486 patients have been
combined in the present meta-analysis, indicating a sta-
tistically significant role of CD44V6 on overall survival
(HR = 1.53, 95 % CI 1.25–1.88, p < 0.0001) and metasta-
sis (RR = 1.76, 95 % CI 1.38–2.25, p < 0.00001) in pa-
tients with OS. As a well-established, widely accepted
method in medical science, immunohistochemistry
(IHC) was used in all these inclusion data. We suggest
that IHC should be adapted to determine the expression
of CD44V6 from biopsy tissue. Our meta-analysis has its
limitations and there are several issues should be consid-
ered. First, although there is no publication bias, poten-
tial publication bias may still exist. Studies with
desirable results might be published more easily, which
can lead to an over-estimation of overall accuracy. Sec-
ond, only the studies that were published in English or
Chinese were included in this meta-analysis, which
could affect our results. Finally, since the rarity of pri-
mary malignant tumors of the bone, accounting for less
than 0.2 % of all cancers [39], the number of included
studies in this meta-analysis was only eight. It might
weaken the reliability of our results. To strengthen our
findings, well-designed clinical studies with larger sam-
ple size should be carried out in the future before the
application of CD44V6 on the metastasis and prognosis
of OS patients. Even the inherent limitations of meta-
analysis is existed, this study represents a quantified syn-
thesis of published studies and emphasizes more attention
about new prognostic biomarkers on OS.
Conclusion
In conclusion, this meta-analysis suggests that CD44V6
over-expression is associated with overall survival rate
and metastasis in osteosarcoma, and may be used as a
prognostic biomarker to guide the clinical therapy for
osteosarcoma.
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